Biotech company shares plummet after ending potentially groundbreaking Alzheimer's drug trial

  • 📰 The Independent
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 59%

Business News News

Business Business Latest News,Business Business Headlines

The company said the decision to end the trial was not based on safety concerns

Biogen, one of the largest biotechs in the world, said the decision to stop the study was not based on safety concerns.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 80. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines